Given the increase in PDE5 levels observed in cardiovascular diseases [52] and in light of the growing evidence pointing to a cardioprotective effect of PDE5 inhibitors in ischemia/reperfusion injuries, mostly through the activation of the mitochondrial respiratory chain [53,54,55], the demonstration of the ability of MmPDE5A2 to influence redox status and energy balance in yeast lays the foundation for the development of targeted studies in mammalian cells. Here, PDE5A is linked to ischemia.